Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study

BACKGROUND: Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobson, Mercedes P, Pazdera, Ladislav, Bhatia, Perminder, Grinnell, Todd, Cheng, Hailong, Blum, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397697/
https://www.ncbi.nlm.nih.gov/pubmed/25880756
http://dx.doi.org/10.1186/s12883-015-0305-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397697/
https://www.ncbi.nlm.nih.gov/pubmed/25880756
http://dx.doi.org/10.1186/s12883-015-0305-5

Ejemplares similares